Budge James

CFO Budge James sold 14,763 shares at blended avg $39.34 on 2026-02-23; stock now -33.8% from 52-week high amid -$1.8M net loss.

Budge James executed three separate sales totaling 14,763 shares for $580,737.39 on 2026-02-23, reducing his post-transaction holdings to 420,132 shares, a 3.4% reduction. The company is currently unprofitable with net income of -$1.8M on revenue of $154.2M, and the stock has fallen 33.8% from its 52-week high while declining 19.9% over 90 days. The CFO's cross-ticker track record shows a 100.00% well-timed rate on prior sells (4 sales with average 90-day return of -19.3%), and his same-ticker history at HNGE shows 3 of 3 prior sells were well-timed at the 90-day mark, establishing a demonstrated pattern of selling ahead of price declines. This latest sale occurs in the context of ongoing stock weakness and reinforces a consistent insider pattern, though current fundamentals show operational challenges that warrant investor attention.

CFO Budge James sells 10,491 shares of HNGE at $48.41; retains 441,174 shares post-transaction

CFO Budge James sold 10,491 shares at $48.41, reducing holdings by 2.3% to 441,174 shares. The sale occurred as HNGE trades 19.5% below its 52-week high of $60.55, in a quarter where the company reported a net loss of $1,844,000.00 on revenue of $154,211,000.00. James has executed three prior sales at HNGE on 2025-11-25, also at this ticker, though measurable returns on those trades remain unavailable. The sale represents a discrete transaction by the CFO at depressed valuations; without visibility into the trading plan mechanics or prior timing accuracy at this specific ticker, the significance remains moderate.

CFO James Budge sells 44,589 shares at $47.47 avg for $2.1M; retains 479,878 shares after -8.5% reduction.

James Budge, Hinge Health's Chief Financial Officer, executed 3 separate sales totaling 44,589 shares for $2,116,778.59 at a blended average price of $47.47, reducing his holdings by 8.5%. The company reported a net loss of $1,844,000.00 in the latest quarter on $154,211,000.00 in revenue, and the stock is trading 20.3% below its 52-week high of $60.55 while down 16.4% over the past 90 days. The scale of the CFO's liquidation—nearly 45,000 shares—alongside the company's profitability challenges and recent share price deterioration warrants investor attention to both the financial trajectory and insider positioning.